top of page

Solutions for Atrial Fibrillation

Atrial fibrillation is the most common cardiac arrhythmia, affecting tens of millions of people worldwide. It is currently a chronic condition with no cure and increased morbidity over time. All current treatments manage symptoms, not the physiological root causes of atrial fibrillation. Based on our preclinical evidence to-date, there is good reason to think human cardiac exosome therapy may be a breakthrough. 

hero_RGB.jpg
about_rhythm.jpg

Founded by cardiologist, electrophysiologist and scientist Dr. Darryl Davis at the University of Ottawa Heart Institute. The company is a preclinical-stage startup focused on addressing a critical unmet need: preventing and treating atrial fibrillation, a chronic, progressive, debilitating, and life-threatening disease.

Our initial focus is on a preventative solution to postoperative atrial fibrillation. RBex is a prophylactic exosome therapy that has demonstrated an 87% reduction in postoperative atrial fibrillation in extensive and published preclinical studies. We are currently raising funds for a first-in-human phase 1 clinical trial.

Latest News, Presentations & Papers

NEWS

"Capital BioVentures Announces Inaugural Cohort for Ottawa Biotech Accelerator Program"

December 3, 2024, BioSpace 

PRESENTATION

“Extracellular Vesicle Therapy for Atrial Fibrillation” and “Arrhythmias in a Model of Chronic Inflammation”

September 26-29, Sydney Australia, at the Asia Pacific Heart Rhythm Society 2024 conference

PAPER

“Atrial Fibrosis and Inflammation in Postoperative Atrial Fibrillation: Comparative Effects of Amiodarone, Colchicine, or Exosomes”

PAPER

“Prevention of atrial fibrillation after open-chest surgery with extracellular vesicle therapy”

June 29, 2023, JCI Insight

NEWS

“Finding its rhythm: Startup seeks $4M in funding for trailblazing atrial fibrillation treatment”

November 15, 2024, Ottawa Business Journal

PRESENTATION

“Exosome-Based Prevention of Postoperative Atrial Fibrillation”

PAPER

“Exploring Patient Viewpoints to Optimize Implementation of a Biological Therapy for Atrial Fibrillation Prevention”

April 16, 2024, CJC Open

PAPER

“Extracellular vesicle microRNA and protein cargo profiling in three clinical-grade stem cell products reveals key functional pathways”

PRESENTATION

“Human extracellular vesicles prevent inflammation and fibrosis in a human model of postoperative atrial fibrillation”

November 10-13, Houston, Texas, at the American Association of Extracellular Vesicles AAEV2024 conference

PAPER

“RNA and the emerging potential of bio-inspired molecules in cardiovascular disease therapies”

June 13, 2024, European Heart Journal

PAPER

“Inactivation of the NLRP3 inflammasome mediates exosome-based prevention of atrial fibrillation”

January 1, 2024, Theranostics

Contact Us

H3214 40 Ruskin St.

Ottawa, Ontario K1Y 4W7 Canada

+1-613-696-7298

  • LinkedIn

© Rhythm Biotherapeutics Inc. All rights reserved.

bottom of page